Helicon peptide

Helicon peptides are a proprietary class of stabilized helical peptides developed by Parabilis Medicines (formerly FogPharma). These peptides are engineered to target intracellular proteins that are typically considered "undruggable" by binding to large, flat protein surfaces with high affinity and selectivity. The Helicon platform enables the development of both direct inhibitors, such as FOG-001 (which targets the β-catenin/TCF4 interaction), and targeted protein degraders (TPD). Specifically, Helicon peptide degraders have been designed to selectively target the agonist-bound, transcriptionally active conformation of the Androgen Receptor (ARON) for ubiquitin-proteasome-mediated degradation, offering a novel therapeutic strategy for castration-resistant prostate cancer.

Brand names

Helicon

Other names

Heliconsstabilized helical peptides